[go: up one dir, main page]

MX2022005034A - Combinacion farmaceutica y uso de la misma. - Google Patents

Combinacion farmaceutica y uso de la misma.

Info

Publication number
MX2022005034A
MX2022005034A MX2022005034A MX2022005034A MX2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A MX 2022005034 A MX2022005034 A MX 2022005034A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
present disclosure
disclosure relates
cancer
colon cancer
Prior art date
Application number
MX2022005034A
Other languages
English (en)
Inventor
Juan Zhang
Original Assignee
Cstone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Suzhou Co Ltd filed Critical Cstone Pharmaceuticals Suzhou Co Ltd
Publication of MX2022005034A publication Critical patent/MX2022005034A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a una novedosa combinación farmacéutica y a un uso de la misma. La combinación farmacéutica puede usarse para tratar el cáncer, tal como el cáncer de colon.
MX2022005034A 2019-11-11 2020-11-11 Combinacion farmaceutica y uso de la misma. MX2022005034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019117155 2019-11-11
PCT/CN2020/128083 WO2021093764A1 (en) 2019-11-11 2020-11-11 Pharmaceutical combination and use thereof

Publications (1)

Publication Number Publication Date
MX2022005034A true MX2022005034A (es) 2022-05-16

Family

ID=75911807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005034A MX2022005034A (es) 2019-11-11 2020-11-11 Combinacion farmaceutica y uso de la misma.

Country Status (11)

Country Link
US (1) US20220387417A1 (es)
EP (1) EP4031179A4 (es)
JP (1) JP2023500385A (es)
KR (1) KR20220103961A (es)
CN (1) CN114901309A (es)
AU (1) AU2020383580A1 (es)
BR (1) BR112022009042A2 (es)
CA (1) CA3160526A1 (es)
IL (1) IL292646A (es)
MX (1) MX2022005034A (es)
WO (1) WO2021093764A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3515938T3 (da) * 2016-09-21 2025-04-07 Cstone Pharmaceuticals Monoklonale antistoffer mod programmeret død 1 (pd-1)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
WO2015053407A1 (ja) * 2013-10-08 2015-04-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AU2015384801B2 (en) * 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
KR20180101488A (ko) * 2016-01-08 2018-09-12 클리어사이드 바이오메디컬, 인코포레이드 아플리베르셉트 및 다른 생물제제로 후안구 장애를 치료하기 위한 방법 및 장치 및 장치
DK3515938T3 (da) * 2016-09-21 2025-04-07 Cstone Pharmaceuticals Monoklonale antistoffer mod programmeret død 1 (pd-1)
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
SG11201908721TA (en) * 2017-04-06 2019-10-30 Hangzhou Dac Biotech Co Ltd Conjugation of a cytotoxic drug with bis-linkage
CA3060514A1 (en) * 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
CN109731019B (zh) * 2019-03-07 2021-07-16 康赋葆(深圳)生物医药科技有限公司 一种具有化疗增效作用的组合物，包括组成、制备及应用
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法

Also Published As

Publication number Publication date
CN114901309A (zh) 2022-08-12
AU2020383580A1 (en) 2022-05-12
US20220387417A1 (en) 2022-12-08
KR20220103961A (ko) 2022-07-25
JP2023500385A (ja) 2023-01-05
EP4031179A4 (en) 2023-10-04
CA3160526A1 (en) 2021-05-20
WO2021093764A1 (en) 2021-05-20
EP4031179A1 (en) 2022-07-27
BR112022009042A2 (pt) 2022-10-11
IL292646A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
MX2019003938A (es) Compuestos espirociclicos.
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
PH12019550224A1 (en) Antitumoral compounds
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
AU366476S (en) Bottle
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX379622B (es) Compuestos espirociclicos
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2017014436A (es) Compuestos biciclicos.
GEP20186893B (en) Pyrazines modulators of gpr6
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MY200161A (en) Bacteria for targeting tumors and treating cancer
WO2019098811A3 (ko) Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2022005034A (es) Combinacion farmaceutica y uso de la misma.
WO2015134603A3 (en) Methods for treating cancer